Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

Equality Impact Assessment (Guidance development) (PDF 84 KB)

Final appraisal determination

Final appraisal determination document (PDF 239 KB)

Committee papers (PDF 606 KB)

Draft guidance

Appraisal consultation document (PDF 232 KB)

Committee papers (PDF 4.72 MB)

Equality impact assessment (Scoping) (PDF 78 KB)

Draft scope (post-referral) (PDF 92 KB)

Provisional matrix (post-referral) (PDF 90 KB)

: Appeal letter (PDF 259 KB)

: Scrutiny letter (PDF 254 KB)

: Response to scrutiny letter (PDF 214 KB)

: Final scrutiny letter (PDF 271 KB)

Appeal decision (PDF 116 KB)

Final appraisal determination document (PDF 192 KB)

Committee papers (PDF 1.22 MB)

Appraisal consultation document (PDF 263 KB)

Committee papers (PDF 4.8 MB)

Final scope (PDF 242 KB)

Final matrix (PDF 299 KB)

Prostate cancer (hormone relapsed, metastatic) - cabazitaxel (after docetaxel): final scope (PDF 87 KB)

Prostate cancer (hormone relapsed, metastatic) - cabazitaxel (after docetaxel): comments table (PDF 140 KB)

Prostate cancer (hormone relapsed, metastatic) - cabazitaxel (after docetaxel): final matrix (PDF 91 KB)